JPMorgan Puts $135 Target on Dianthus After Starting Coverage
Lead drug claseprubart (also known as DNTH103) plus $1.2B cash into 2030.
/ 1647 items
#XY↓
Karyopharm Warns of Going-Concern Risk Without New Funding by Mid-October
Karyopharm skipped a $15.8M loan payment and won a pause until Oct. 15. Cash may last only that long without a new raise or deal.
Morgan Stanley Cuts Novo Nordisk to Underweight Over Growth Slowdown and Semaglutide Patent Cliff
Semaglutide still drives most of Novo Nordisk’s sales. Morgan Stanley and other banks warn the mid-2030s patent cliff and Eli Lilly competition look underpriced.
FDA Extends Review of Exelixis Colorectal Cancer Combo to March 2027
FDA adds three months to its review of Exelixis’ zanzalintinib plus Tecentriq for metastatic colorectal cancer after a major amendment.
BBOT Stock Slides as Investors Price a Smaller Opportunity
BBOT dropped ~38% in two days. Stifel, Leerink, Canaccord, and JPMorgan lowered targets but did not downgrade ratings. JPMorgan sees a disconnect vs pipeline value.
Axogen Stock Drops After $209 Million Share Sale to Fund NerveTape Deal
Axogen will use proceeds from a $208.7 million stock offering to buy BioCircuit Technologies and its NerveTape device, the first FDA-cleared sutureless option for peripheral nerve repair.